385 related articles for article (PubMed ID: 33302598)
1. Understanding Mechanisms Underlying Non-Alcoholic Fatty Liver Disease (NAFLD) in Mental Illness: Risperidone and Olanzapine Alter the Hepatic Proteomic Signature in Mice.
Rostama B; Beauchemin M; Bouchard C; Bernier E; Vary CPH; May M; Houseknecht KL
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33302598
[TBL] [Abstract][Full Text] [Related]
2. Exploring mechanisms of increased cardiovascular disease risk with antipsychotic medications: Risperidone alters the cardiac proteomic signature in mice.
Beauchemin M; Geguchadze R; Guntur AR; Nevola K; Le PT; Barlow D; Rue M; Vary CPH; Lary CW; Motyl KJ; Houseknecht KL
Pharmacol Res; 2020 Feb; 152():104589. PubMed ID: 31874253
[TBL] [Abstract][Full Text] [Related]
3. Olanzapine leads to nonalcoholic fatty liver disease through the apolipoprotein A5 pathway.
Li R; Zhu W; Huang P; Yang Y; Luo F; Dai W; Shen L; Pei W; Huang X
Biomed Pharmacother; 2021 Sep; 141():111803. PubMed ID: 34146854
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of hepatic fatty acid transporters and inhibition/down-regulation of hepatic OCTN2 contribute to olanzapine-induced liver steatosis.
Jiang T; Zhang Y; Bai M; Li P; Wang W; Chen M; Ma Z; Zeng S; Zhou H; Jiang H
Toxicol Lett; 2019 Nov; 316():183-193. PubMed ID: 31437515
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms Underlying Antipsychotic-Induced NAFLD and Iron Dysregulation: A Multi-Omic Approach.
May M; Barlow D; Ibrahim R; Houseknecht KL
Biomedicines; 2022 May; 10(6):. PubMed ID: 35740245
[TBL] [Abstract][Full Text] [Related]
6. Olanzapine-induced nonalcoholic fatty liver disease: The effects of differential food pattern and the involvement of PGRMC1 signaling.
Zhu Z; Cao T; Chen H; Zhang B; Lin C; Cai H
Food Chem Toxicol; 2023 Jun; 176():113757. PubMed ID: 37019375
[TBL] [Abstract][Full Text] [Related]
7. A novel role for dopamine signaling in the pathogenesis of bone loss from the atypical antipsychotic drug risperidone in female mice.
Motyl KJ; Beauchemin M; Barlow D; Le PT; Nagano K; Treyball A; Contractor A; Baron R; Rosen CJ; Houseknecht KL
Bone; 2017 Oct; 103():168-176. PubMed ID: 28689816
[TBL] [Abstract][Full Text] [Related]
8. The effects of perfluorooctanoate on high fat diet induced non-alcoholic fatty liver disease in mice.
Li X; Wang Z; Klaunig JE
Toxicology; 2019 Mar; 416():1-14. PubMed ID: 30711707
[TBL] [Abstract][Full Text] [Related]
9. Liver sympathetic denervation reverses obesity-induced hepatic steatosis.
Hurr C; Simonyan H; Morgan DA; Rahmouni K; Young CN
J Physiol; 2019 Sep; 597(17):4565-4580. PubMed ID: 31278754
[TBL] [Abstract][Full Text] [Related]
10. Ubiquitin-Specific Peptidase 10 (USP10) Inhibits Hepatic Steatosis, Insulin Resistance, and Inflammation Through Sirt6.
Luo P; Qin C; Zhu L; Fang C; Zhang Y; Zhang H; Pei F; Tian S; Zhu XY; Gong J; Mao Q; Xiao C; Su Y; Zheng H; Xu T; Lu J; Zhang J
Hepatology; 2018 Nov; 68(5):1786-1803. PubMed ID: 29698567
[TBL] [Abstract][Full Text] [Related]
11. Curcumin Ameliorates Nonalcoholic Fatty Liver Disease through Inhibition of
Lee DE; Lee SJ; Kim SJ; Lee HS; Kwon OS
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31717261
[TBL] [Abstract][Full Text] [Related]
12. Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease.
Povero D; Eguchi A; Li H; Johnson CD; Papouchado BG; Wree A; Messer K; Feldstein AE
PLoS One; 2014; 9(12):e113651. PubMed ID: 25470250
[TBL] [Abstract][Full Text] [Related]
13. Human germline hedgehog pathway mutations predispose to fatty liver.
Guillen-Sacoto MJ; Martinez AF; Abe Y; Kruszka P; Weiss K; Everson JL; Bataller R; Kleiner DE; Ward JM; Sulik KK; Lipinski RJ; Solomon BD; Muenke M
J Hepatol; 2017 Oct; 67(4):809-817. PubMed ID: 28645738
[TBL] [Abstract][Full Text] [Related]
14. APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice.
Cheng X; Yamauchi J; Lee S; Zhang T; Gong Z; Muzumdar R; Qu S; Dong HH
J Biol Chem; 2017 Mar; 292(9):3692-3705. PubMed ID: 28115523
[TBL] [Abstract][Full Text] [Related]
15. FBXW7 suppresses HMGB1-mediated innate immune signaling to attenuate hepatic inflammation and insulin resistance in a mouse model of nonalcoholic fatty liver disease.
Zhang C; Chen F; Feng L; Shan Q; Zheng GH; Wang YJ; Lu J; Fan SH; Sun CH; Wu DM; Li MQ; Hu B; Wang QQ; Zhang ZF; Zheng YL
Mol Med; 2019 Jun; 25(1):29. PubMed ID: 31215394
[TBL] [Abstract][Full Text] [Related]
16. Intracellular lipids are an independent cause of liver injury and chronic kidney disease in non alcoholic fatty liver disease-like context.
Monteillet L; Gjorgjieva M; Silva M; Verzieux V; Imikirene L; Duchampt A; Guillou H; Mithieux G; Rajas F
Mol Metab; 2018 Oct; 16():100-115. PubMed ID: 30100243
[TBL] [Abstract][Full Text] [Related]
17. Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study.
Morlán-Coarasa MJ; Arias-Loste MT; Ortiz-García de la Foz V; Martínez-García O; Alonso-Martín C; Crespo J; Romero-Gómez M; Fábrega E; Crespo-Facorro B
Psychopharmacology (Berl); 2016 Dec; 233(23-24):3947-3952. PubMed ID: 27620899
[TBL] [Abstract][Full Text] [Related]
18. LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD).
Soares e Silva AK; de Oliveira Cipriano Torres D; dos Santos Gomes FO; dos Santos Silva B; Lima Ribeiro E; Costa Oliveira A; dos Santos LA; de Lima Mdo C; Pitta Ida R; Peixoto CA
PLoS One; 2015; 10(4):e0123787. PubMed ID: 25875942
[TBL] [Abstract][Full Text] [Related]
19. Involvement of G protein-coupled receptor kinase 2 (GRK2) in the development of non-alcoholic steatosis and steatohepatitis in mice and humans.
Cruces-Sande M; Vila-Bedmar R; Arcones AC; González-Rodríguez Á; Rada P; Gutiérrez-de-Juan V; Vargas-Castrillón J; Iruzubieta P; Sánchez-González C; Formentini L; Crespo J; García-Monzón C; Martínez-Chantar ML; Valverde ÁM; Mayor F; Murga C
Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3655-3667. PubMed ID: 30261289
[TBL] [Abstract][Full Text] [Related]
20. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
